


Figure 1



Drug
Hollow Fiber Wall
Hollow Fiber Lumen
Peripheral compartment
Bacteria
Waste Media
Central Compartment
fresh Media

Figure 2



R1
R5
R8
R2
R4
R3
R6
R7
R12
R9
R11
R10
R13
R14
MAC log10 CFU/mL
9
8
7
6
5
4
3
2
1
0
2
4
6
8
10
12
14
16
18
20
22
24
26
28
Study Day

Figure 3




Figure 4B




Figure 4A




Figure 5B




Figure 5A




Figure 6B




Figure 6A




Figure 7B




Figure 7A



clofazimine (ng/mL)
800
600
400
200
0
ΔΔQTcF (ms)
40
30
20
10
0
-10
1
2
3
4
8
12
26
52
Week
▲ ΔΔQTcF RHB-104 □ clofazimine plasma concentrations of RHB-104

Figure 8



Placebo Adjusted ΔQTcF (ms)
75
50
25
0
-25
-50
0
500
1000
1500
clofazimine concentration (ng/mL)
RHB-104
Placebo
Mean Predicted
90% CI

Figure 9



ΔΔQTcF (ms)
80
60
40
20
0
0
500
1000
1500
clofazimine concentration (ng/mL)
Area A
Area B
Week 26
Mean Predicted
Simulated BID, TIW Week 52 (40 mg CLZ)
Week 52
Simulated BID, TIW Week 26 (40 mg CLZ)

Figure 10